Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
| Autor: | Ricardo Costa, Alfred Rademaker, Benedito A. Carneiro, Corinne H. Miller, Manali Bhave, Jason B. Kaplan, Sarah M. Talamantes, Young Kwang Chae, R. Costa, Devalingam Mahalingam |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Alectinib
Oncology medicine.medical_specialty brigatinib Brigatinib 03 medical and health sciences 0302 clinical medicine Internal medicine medicine ROS1 Anaplastic lymphoma kinase ceritinib alectinib 030212 general & internal medicine Lung cancer crizotinib Crizotinib Ceritinib business.industry Cancer anaplastic lymphoma kinase medicine.disease 030220 oncology & carcinogenesis business medicine.drug Meta-Analysis |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Rubens Barros Costa 1 , Ricardo L.B. Costa 2 , Sarah M. Talamantes 3 , Jason B. Kaplan 1 , Manali A. Bhave 1 , Alfred Rademaker 4 , Corinne Miller 5 , Benedito A. Carneiro 6 , Devalingam Mahalingam 1 and Young Kwang Chae 1 1 Developmental Therapeutics Program, Northwestern University, Chicago, IL, USA 2 Department of Breast Oncology, Lee Moffitt Cancer Center, Tampa, USA 3 Northwestern University, Feinberg School of Medicine, Chicago, IL, USA 4 Northwestern University, Department of Preventive Medicine, Chicago, IL, USA 5 Galter Health Sciences Library, Northwestern University, Chicago, IL, USA 6 Life Span Cancer Institute, Providence, RI, USA Correspondence to: Rubens Barros Costa, email: barros4@yahoo.com Keywords: crizotinib; ceritinib; alectinib; brigatinib; anaplastic lymphoma kinase Received: January 20, 2018 Accepted: April 04, 2018 Published: April 24, 2018 ABSTRACT Introduction: Anaplastic lymphoma kinase ( ALK ) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Materials and Methods: A systematic literature search was performed in July 2017. Studies evaluating US FDA approved doses of one of the following ALK inhibitors: Crizotinib, Ceritinib, Alectinib or Brigatinib as monotherapy were included. Data were analyzed using random effects meta-analysis for absolute risks (AR), study heterogeneity, publication bias and differences among treatments. Results: Fifteen trials with a total of 2,005 patients with evaluable toxicity data were included in this report. There was significant heterogeneity amongst different studies. The pooled AR of death and severe adverse events were 0.5% and 34.5%, respectively. Grade 3/4 nausea, vomiting, diarrhea, and constipation were uncommon: 2.6%, 2.5%, 2.7%, 1.2%, respectively. Conclusions: ALK inhibitors have an acceptable safety profile with a low risk of treatment-related deaths. Important differences in toxicity profile were detected amongst the different drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|